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Endothelial dysfunction is a pathological status of the vascular system, which can be broadly defined as an imbalance
between endothelium-dependent vasoconstriction and vasodilation. Endothelial dysfunction is a key event in the
progression of many pathological processes including atherosclerosis, type II diabetes and hypertension. Previous
reports have demonstrated that pro-inflammatory/immunoeffector cytokines significantly promote endothelial
dysfunction while numerous novel anti-inflammatory/immunosuppressive cytokines have recently been identified
such as interleukin (IL)-35. However, the effects of anti-inflammatory cytokines on endothelial dysfunction have received
much less attention. In this analytical review, we focus on the recent progress attained in characterizing the direct and
indirect effects of anti-inflammatory/immunosuppressive cytokines in the inhibition of endothelial dysfunction.
Our analyses are not only limited to the importance of endothelial dysfunction in cardiovascular disease progression,
but also expand into the molecular mechanisms and pathways underlying the inhibition of endothelial dysfunction by
anti-inflammatory/immunosuppressive cytokines. Our review suggests that anti-inflammatory/immunosuppressive
cytokines serve as novel therapeutic targets for inhibiting endothelial dysfunction, vascular inflammation and
cardio- and cerebro-vascular diseases.
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The endothelium has long been viewed not only as a
monolayer of endothelial cells (EC) lining the lumen of
all blood vessels to function as a protective biocompat-
ible barrier between tissues and circulating blood, but
also as a highly specialized, heterogeneous [1], dynamic,
disseminated organ [2] with paracrine and autocrine
functions which respond to alterations of hemodynamic
forces and chemical stimuli. In its entirety, the endothe-
lium is composed of 1 to 6 × 1013 EC covering a surface
area of more than 1,000 square meters [3,4]. Endothelial
dysfunction is a systemic pathological condition, which* Correspondence: xfyang@temple.edu
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unless otherwise stated.can be defined as an imbalance between endothelium-
dependent vasoconstriction and vasodilation. Endothelial
dysfunction initiates a number of events that trigger EC
activation, which predisposes the vessel wall to be stimu-
lated by cardiovascular risk factors [5]. Specifically, endo-
thelial dysfunction is associated with reduced nitric oxide
(NO) production, increased reactive oxygen species (ROS)
production, upregulation of cytokines and chemokines,
decreased anticoagulant properties and enhanced platelet
aggregation and leukocyte adherence. One related but
more specific term known as endothelial activation is
characterized by the upregulation of EC adhesion mole-
cules such as intercellular adhesion molecule-1 (ICAM-1),
vascular cell adhesion molecule-1 (VCAM-1) and in-
creased secretion of cytokines and chemokines, which fa-
cilitates trans-EC migrations of monocytes, macrophages,
dendritic cells, leukocytes, B cells, natural killer cells, and
T cells [6]. Perturbations in EC functions play importantd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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ing cardiovascular diseases, metabolic syndrome, systemic
inflammatory diseases, and sepsis [7].
Cytokines, including lymphocyte-generated lympho-
kines, monocyte-produced monokines, chemokines [8],
interferons, interleukins, adipocyte-secreted adipokines
[9] and muscle-generated myokines [10] act by binding
to their specific receptors in concert with specific cyto-
kine inhibitors and soluble cytokine receptors, to regu-
late innate and adaptive immune responses. They are
produced by many types of cells such as vascular EC, in re-
sponse to the stimulations caused by metabolite-related
danger signal-associated molecular patterns (DAMPs)
[11] and pathogen-associated molecular patterns (PAMPs)
[12] that include bacterial endotoxins, injury, or inflam-
matory mediators [13]. Cytokines can be divided into
pro-inflammatory and anti-inflammatory (immunosuppres-
sive) cytokines. Anti-inflammatory cytokines may either
inhibit pro-inflammatory cytokine synthesis or control pro-
inflammatory cytokine-mediated cellular activities [14,15].
Numerous reviews have been published on the roles of
pro-inflammatory cytokines on eliciting endothelial dys-
function [16-26] and many pro-inflammatory cytokine
antagonists have been developed. These new cytokine
anta-gonists include: a) etanercept, infliximab, adalimu-
mab and certolizumab pegol as tumor necrosis factor-α
(TNF-α) antagonists; b) Sant1, Sant5, and Sant7 as inter-
leukin-6 (IL-6) receptor superantagonists; c) anakinra as
IL-1 receptor antagonist; d) IL-1 receptor antagonist (IL-
1Ra) as IL-1α and IL-1β antagonists; e) IL-18BP as IL-
18 antagonist, and f ) soluble Endoglin as transforming
growth factor-β (TGF-β) antagonist [27]. Potential the-
rapeutic effects of these new inflammatory cytokine an-
tagonists on endothelial dysfunction remain unclear. In
addition, previous reports showed that anti-inflammatory
cytokines IL-10, members of the TGF-β family, and pro-
resolving lipid mediators (such as lipoxins, resolvins, and
protectins) may suppress pro-inflammatory signaling [28].
Moreover, recent studies have shown that the spectrum of
anti-inflammatory cytokinesis expanding [29], which may
hold promise for developing potential novel therapeutics
and tools for the diagnosis and management of diseases
[27]. However, the roles of anti-inflammatory cytokines
in endothelial dysfunction have not been extensively ana-
lyzed. Therefore, the protective effects of anti-inflammatory
cytokines against endothelial dysfunction are the focus of
this review (Figure 1).
Endothelium-dependent regulation of vascular tone
Recent studies have demonstrated that endothelial dys-
function is a mechanistic link between atherosclerotic risk
factors and an early development of vascular diseases,
which is an independent predictor of future cardiovascular
pathologies in patients with atherogenic risk factors orischemic heart disease [30]. Although endothelial dysfunc-
tion may have a more generalized definition, current prac-
tical definition is related to the endothelial dysfunction of
vascular tone. A healthy endothelium modulates vascular
tone by producing numerous vascular dilators and con-
strictors. In clinical practices, flow-mediated dilation test
is the standard tool used to assess endothelial function
[31]. In addition, various reactivity tests, coupled with
techniques measuring skin blood flux, are used to non-
invasively explore both endothelial and neurovascular
microvascular functioning in humans [32].
First described by Mulvany and Halpern, vascular tone
is measured by using myography in mouse models [33].
This instrument is used for the examination of isolated ar-
teries, with internal diameters between 100–400 μm that
are independent of homeostatic mechanisms such as
blood flow or autonomic nervous control [34]. The condi-
tions near the physiological setting obtained in myograph
allows in-depth characterization of intrinsic vascular tone
reactions to physiological and pharmacological stimuli
[35]. According to active tension-length relation, force
production and the sensitivity of arteries to different ago-
nists are dependent on the extent of stretch [36]. There
are two types of myographs for measuring vascular func-
tion and studying vascular tones known as the pressure
myograph and wire myograph (also see DMT website for
an introduction http://www.dmt.dk/default.asp?Action=-
Details&Item=543). Pressure myograph may have some
advantages over wire myograph such like: 1) micro resist-
ance arteries with internal diameters of less than 500 μm
[37] can be studied whereas wire myograph is limited to
large conduit arteries; 2) the risk to damage endothelium
by wire is reduced; 3) the nature morphology of the arter-
ies is maintained; and 4) the potential effects of a wide
range of pressures and shear stress on artery dimension
can be studied [35]. In addition, studying microarteries
can be more informative than examining larger conduit
arteries to understand the pathophysiological and molecu-
lar mechanisms underlying altered vascular tone in certain
mouse models of cardiovascular diseases such as hyper-
tension [35]. For example, endothelial dysfunction can be
found in 2nd order mesenteric arteries but not in the
aortic rings of mice fed with a high fat diet for 8 weeks
[38]. In vessel rings pre-contracted with phenylephrine
(PE; 1 μM) [39], vascular tone reactivity can be grouped
into endothelium-dependent reactivity (to acetylcholine,
ACh; 10 nM to 33 μM) and endothelium-independent re-
activity (to sodium nitroprusside, SNP; 1 nM to 10 μM),
therefore we focus our discussion mainly on endothelium-
dependent pathways.
Since high myocardial oxygen extraction occurs at basal
conditions, additional metabolic demands may be met by
increasing the myocardial blood supply. The coronary ar-
tery is capable of increasing the basal flow by at least three
Figure 1 A new working model: Regulatory T cells and immunosuppressive/anti-inflammatory cytokines inhibit endothelial
dysfunction. In physiological status, the interaction between endothelium-dependent vasoconstrictors (including Ang II, ET-1, ROS) and vasodilators
(NO, EDHF and PGI2) maintain the endothelial function and equilibrium of vascular tone. The impairment of the balance between the vasoconstrictors
and vasodilators is generally defined as the endothelial dysfunction. Under cardiovascular diseases risk factors stimuli, when vasodilation
pathways being impaired or vasoconstriction being activated, endothelial dysfunction occurs. Regulatory T cells (Tregs) act on endothelial
cells via cell-cell-interaction and/or immunosuppressive/antiinflammatory cytokines to inhibit endothelial dysfunction and restore normal
vascular tone.
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defined as “coronary artery reserve”. This remarkable fea-
ture is regulated by various vasodilators and vasoconstric-
tors produced by coronary artery endothelial cells [40].
Not limited to coronary artery endothelium, endothelium
generally are capable of producing vasodilators such as
NO, prostacyclin (PGI2), and endothelium-derived hyper-
polarizing factor (EDHF) as well as vasoconstrictors such
as endothelin-1 (ET-1), angiotensin II (Ang II), and free




Among several endothelium-dependent pathways that
control vascular tone, the NO pathway is the most prom-
inent in macrovasculature. NO is a key endothelium-
derived relaxing factor, produced through the conversion
of L-arginine to L-citrulline by the endothelial nitric oxide
synthase (eNOS). Once produced in EC, NO diffuses
freely into the vascular smooth muscle cells (SMC) where
it activates soluble guanylyl cyclase (sGC), which in turncatalyzes the formation of cyclic guanosine monopho-
sphate (cGMP) and finally leads to the relaxation of the
vascular smooth muscle [42]. NO is synthesized by a fam-
ily of NO synthases (NOS) that include neuronal NOS
(nNOS), eNOS and inducible NOS (iNOS). These three
NOS share 50-60% homology at the amino acid sequence
and all have an N-terminal oxygenase domain with heme-,
L-arginine- and tetrahydrobiopterin (BH4) binding do-
mains, a central calmodulin (CaM)-binding domain, a
C-terminal reductase domain with nicotinamide adenine
dinucleotide phosphate (NADPH), flavin adenine dinucleo-
tide (FAD), and a flavin mononucleotide (FMN) binding
site [43]. Biochemical and mechanical regulations of eNOS
activity play an important role in physiological and
pathophysiological responses. eNOS enzymatic activity
can be regulated at multiple levels including gene tran-
scription, mRNA stability, substrate, co-factor availability,
post-translational modifications, and protein-protein inter-
action with heat shock protein 90(hsp90) and caveolins
[44]. Phosphorylation of eNOS can take place at seven dif-
ferent phosphorylation sites at specific tyrosine (Y), serine
(S) and threonine (T). The identified Y sites localize to Y81
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S1177, and the T site localizes to T495 (based on the hu-
man eNOS sequence nomenclature) [43]. AKT-1-mediated
phosphorylation of S615 and S1177 cooperate to enhance
NO generation from eNOS at resting calcium levels, al-
though there is a yin-yang relationship between T495 and
S1177 with phosphorylation of one being correlated with
dephosphorylation of the other. In addition, phosphoryl-
ation of eNOS at S114 decreases eNOS activity [43].
Mechanical shear stress activates eNOS by the phosphor-
ylation of the serine residue 1177 and activation of protein
kinase B (PKB, AKT), which itself is phosphorylated by
phosphatidylinositol-3-kinase (PI3K) [45]. Different from
the maintained phosphorylation of serine residue of eNOS
in shear stress–stimulated cells, serine 1177 phosphoryl-
ation of eNOS in bradykinin-stimulated cells is transient.
This eNOS activation requires an elevation in intracellular
free calcium concentration, formation of a complex with
calmodulin and the removal of the inhibitory caveolin
from the activated eNOS complex, although NO produc-
tion is not affected by the components of PI3K-AKT path-
way [46].
Besides being the main determinant of the basal vascu-
lar tone, NO serves as a natural counterpart to the actions
of potent endothelium-derived contracting factors such as
Ang II and ET-1. In turn, these factors can also regulate
the expression of NOS and NO production [47-49]. Re-
duced NO bioavailability, resulting from either insufficient
production or increased degradation of NO, is one of the
dominant features of endothelial dysfunction. eNOS re-
quires critical cofactors, such as FAD, NADPH and BH4,
to facilitate NO production [50]. In the absence of ad-
equate levels of L-arginine or an essential amount of the
cofactors, eNOS may become uncoupled and generate
ROS including superoxide anions (O2
−), and hydrogen per-
oxide (H2O2) instead of nitrogen species [51]. Therefore,
the availabilities of L-arginine and eNOS cofactors FAD,
NADPH, and BH4 are very important for NO availability
and endothelial function.
Endothelium-derived hyperpolarizing factor
EDHF pathway also plays a significant role in vascular
tone regulation, especially in small resistant vessels. It
triggers potassium ions (K+) efflux, which prevents
voltage-dependent calcium channel activation, leading
to a decrease of the intracellular calcium concentration
and relaxation of vascular SMC [52]. The chemical
identity of EDHF has not yet been identified. In some
cases, it has been found that members of the arachi-
donic acid (AA) derivatives known as eicosatrienoic
acids (EETs) can mediate vasodilation. Agonists such as
bradykinin stimulate endothelial G protein-coupled re-
ceptors (GPCR) provoking an increase in intracellular
calcium in the EC, which activates phospholipase A2(PLA2) mediated AA production. AA metabolism by cyto-
chrome P450 2C (CYP4502C) generates EET, which can
stimulate calcium dependent potassium (KCa
+ ) channels.
Open KCa
+ channels allows for an efflux and accumulation
of K+ into the myoendothelial space that triggers the trans-
mission of endothelial cell hyperpolarization to the vascu-
lar smooth muscle via gap junctions. In turn, smooth
muscle cell hyperpolarization results in relaxation by the
closing of voltage-gated channels leading to a fall in Ca2+
concentration and subsequent vasodilation [53]. Myoen-
dothelial gap junctions play an important role in electro-
tonic spread hyperpolarization between EC and SMC. In a
number of blood vessels in which myoendothelial coup-
ling is strong, such as in the rat mesenteric artery, the
EDHF pathway occurs. While in adult rat femoral ar-
tery, in which the smooth muscle and endothelial layers
are not coupled electrically, EDHF pathway does not
occur even though acetylcholine evokes hyperpolarization
in the EC [54]. KCa
+ channels have been divided into
three types, small-conductance (SK-Ca
+ ), intermediate-
conductance (IKCa
+ ) and large-conductance (BKCa
+ ) chan-
nels. A combination of apamin (a specific inhibitor of
SKCa
+ ) and charybdotoxin (a non-selective inhibitor of
BKCa
+ , IKCa
+ and voltage-dependent K+-channels), which
has been demonstrated to act selectively on endothelium
[55], can completely block EHDF-mediated relaxation
[56,57]. SKCa
+ and IKCa
+ channels are abundant in EC and
their activation clearly engages in EDHF-induced vasodila-
tion [58]. Meanwhile, as a specific inhibitor of BKCa
+ , iber-
iotoxin cannot substitute for charybdotoxin or exclude the
role of BKCa
+ in EDHF-mediated response [59]. BKCa
+ has
been identified in SMC along with three other types of
K+ channels, voltage-dependent K+(Kv) channels, ATP-
sensitive K+(KATP) channels, and inward rectifier K+(Kir)
channels [60]. In addition, a study found that IKCa
+ chan-
nels are expressed in proliferative SMC rather than nor-
mal SMC, which in turn can define the physiological
properties of vascular smooth muscle [61].
Besides K+ and EETs, H2O2 also activates calcium-
dependent potassium channels and has been demon-
strated to function as a pivotal EDHF [62]. H2O2 plays
an important role in coronary auto-regulation in cooper-
ation with NO and adenosine [63]. In mouse mesenteric
arteries, catalase can inhibit ACh-induced endothelium-
dependent relaxation and cause hyperpolarization by cata-
lyzing the decomposition of H2O2 to water and oxygen.
This suggests H2O2 may also perform the role of EDHF
in mouse mesenteric arteries [64]. However, catalase does
not inhibit non-NO-, non-PGI2-mediated vasodilation
in all arteries [63-65]. Upon ACh stimulation in eNOS
knockout mice, the endothelium-produced H2O2 reduces
dramatically, which indicates that eNOS is a major source
of H2O2. In addition, a redox variant of NO, nitroxyl anion
(NO−), has been proved to be an endogenously derived
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aorta from Ang II-treated hypertensive mice [66,67]. Re-
cently, H2S has also been suggested to be an EDHF. H2S
causes vascular EC and SMC hyperpolarization and vaso-
dilation by activating the KATP, SKCa
+ and IKCa
+ channels
through cysteine S-sulfhydration [68].
It has long been accepted that, unlike NO, which in-
duces vasodilation in large conductance arteries, EDHF
regulates vascular tone and reactivity in small resistance
vessels [69]. However, recent in vivo studies found that
cytochrome P-450-related EDHF is involved in the regu-
lation of the peripheral conduit artery diameter at rest
but not in the control of the basal vascular resistance in
the healthy human forearm [70]. After inhibition of NO
and prostacyclin, the inhibition of EET synthesis further
decreases radial arterial blood flow and diameter. This
indicates that EETs plays a potential compensatory role
in maintaining basal tone when NO availability is dimin-
ished. In addition, it has been demonstrated that in
hypercholesterolemia KCa
+ channel-mediated vasodilation
compensates for the reduced NO bioavailability [71].
Furthermore, the activity of EDHF is much higher in in-
dividuals with multiple risk factors than that in healthy
subjects when compared to NO.
Prostacyclin
Prostacyclin, also termed as PGI2 is also an endothelium-
released effective vasodilator, which functions by binding
to GPCRs(G-protein-coupled receptors) to stimulate the
production of cyclic adenosine monophosphate (cAMP)
that subsequently activates protein kinase A (PKA) and
leads to smooth muscle relaxation and vasodilation. PGI2
also inhibits vasoconstriction, platelet activation and fur-
ther coagulation by counteracting the effects of the vaso-
constrictor thromboxane A2 (TXA2). PGI2 and TXA2 are
produced from AA metabolism mediated by cyclooxygen-
ase (COX). There are two isoforms of COX, which mainly
differ in their pattern of expression. COX-1 is expressed
in most tissues, whereas COX-2 is usually absent but in-
duced by various physiologic stimuli. COX-1 mostly pro-
duces TXA2 while the induction of COX-2 is associated
with an increase in PGI2 production [72]. P38 and P44/42
mitogen-activated protein kinase (MAPK) pathways medi-
ate the induction of COX-2. In recent years, the wildly ac-
cepted COX-2-dependent PGI2 production pathway has
been challenged by the direct measurement of circulating
PGI2 levels rather than by the use of urinary markers,
which unveiled that it is COX-1, not COX-2, that is re-
sponsible for PGI2 production in healthy individuals [73].
The opposite conclusions engender controversy of PGI2
testing [74], although specific COX-2 inhibitors increase
the risk of cardiovascular events, which supports that vas-
cular COX-2 is an important protein for maintaining
vascular hemostasis [72-74].The three endothelium-dependent vasodilation path-
ways, NO, EDHF, and PGI2 do not appear to be mutually
exclusive but act synergistically in a complex manner to
maintain the vasculature health. In addition, the roles of
these three components may vary among the vascular
beds in different sizes and tissue locations [69]. Moreover,
different pathways vary in time course. Many studies have
shown that EDHF is more important during the earlier
phase of endothelial dysfunction while NO and PGI2 are
primarily responsible for later and more sustained parts of
the vasodilator in response to acetylcholine or bradykinin
in various arteries [75,76].
Endothelium-derived vasoconstrictors
Reactive oxygen species
As analyzed in our recent review [77], ROS can be derived
from the transfer of electrons to molecular oxygen in the
mitochondrial respiratory systems [78,79] or produced by
the activity of NADPH oxidases, which is co-localized
with eNOS in subcellular compartments within EC [80].
This observation provides a direct link between NADPH
oxidase and the endothelial function in humans. Small
and transient amounts of O2
− can be beneficial for the
endothelial function, through activation of eNOS via Src
(a homolog gene highly similar to the v-src gene of Rous
sarcoma virus)/PI3-kinase/Akt pathway [51]. High levels
of ROS generated in pathological situations will reduce
NO bioavailability by the binding of O2
− to form peroxy-
nitrite (ONOO−). This ONOO− coupling with NO re-
sults in an imbalance of vascular tension. In addition,
NADPH-derived H2O2 impairs endothelial function by
amplifying itself in vascular disease [81]. Elevated levels
of ROS have been associated with endothelial dysfunction
developed in diabetes mellitus, hypertension, hypercholes-
terolemia, obesity, atherosclerosis [82-86] and sepsis [87].
In addition, several inflammatory cytokines are induced
by oxidant stress [88,89] while cytokines themselves in
turn lead to increased levels of ROS and reactive nitrogen
species (RNS) in acute or chronic inflammation [90].
Angiotensin II
Ang II is part of the renin-angiotensin system that causes
vasoconstriction, which increases blood pressure. Ang II
stimulates Gq protein in vascular SMC, which increases
intracellular calcium levels by an IP3-dependent mechan-
ism that consequently leads to contraction. In addition,
Ang II enhances vascular arginase activity that impairs
NO production by decreasing L- arginine availability
[91,92]. It has been demonstrated that the p38 MAPK
pathway participates in this arginase upregulation [93].
Moreover, Ang II also increases superoxide produc-
tion, which leads to eNOS uncoupling [48,94] in EC.
Meanwhile, other studies demonstrated that the activa-
tion of the COX-1 pathway is involved in Ang II-
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resistance arteries [95,96].
Endothelin-1
ET-1, a 21-aa peptide released by EC, is a natural counter-
part of NO, which is normally kept in balance by many
mechanisms. ET-1 and NO take part in a paracrine regu-
lation of each other, and the release of ET-1 is blocked
by endothelium-derived NO [97,98]. In pathological sit-
uations, ET-1 upregulates the expression of caveolae-1,
which appears to be a key negative regulator protein for
eNOS activity which leads to eNOS inhibition [99]. In
addition, ET-1 can also increase ROS production attrib-
uting to NO degradation [100]. Selective endothelin re-
ceptor type A (ETA) and dual (ETA + ETB) antagonists
improve NO bioavailability and endothelial function in
pathological situations. Transgenic mice that overex-
press ET-1 specifically in EC (eET-1) have an increase
of endothelial dysfunction, vascular remodeling, oxidative
stress, and inflammation [100,101]. Recently, a study dem-
onstrated that ET-1-induced vascular hypertrophy and
oxidative stress participate in innate immunity system ac-
tivation [102,103]. Overexpression of ET-1 in EC causes
an increase in monocytes/macrophage infiltration into ad-
ventitia, which is similar to the findings in mice infused
with Ang II [104]. Colony stimulation factor-1 (CSF1)
deficiency, a gene mutation impairing monocyte and
macrophage production and maturation, can prevent
this vascular damage. This finding provides evidence of
the roles of monocyte/macrophage as well as innate im-
munity in ET-1-induced vascular injury.
Role of anti-inflammatory cytokines in endothelial
dysfunction
The delicate balance between pro- and anti-inflammatory
cytokines determines the net effect of an inflammatory re-
sponse. Perturbations in this equilibrium can drive the
host defense immune response either towards chronic
inflammation (pro-inflammatory) or towards healing
(anti-inflammatory). Exposure of endothelial cells to
pro-inflammatory cytokines leads to transient and re-
versible endothelial dysfunction [105,106]. A number of
anti-inflammatory treatment strategies improve endo-
thelial function by preventing pro-inflammatory cyto-
kine synthesis. Anti-inflammatory cytokines are a series
of immune-regulatory molecules that control the pro-
inflammatory cytokines response, which consequently re-
duces inflammation and promotes healing. In addition, an
elevation in the level of anti-inflammatory cytokines
can also be found in the development of vascular dis-
ease [107], which reflects an early compensatory mech-
anism and serves as an indicator of pro-inflammatory
reactions. Major anti-inflammatory cytokines include
IL-1Ra, IL-4, IL-10, IL-11, IL-13 and TGF-β. Severalnewly found cytokines, such as IL-33, IL-35, and IL-37
also participate in regulating the function of EC. The
following will discuss two of these anti-inflammatory
cytokines including IL-10 and TGF-β in detail.
Interleukin-10
IL-10 is an anti-inflammatory cytokine produced by many
types of immune cells, such as monocytes, macrophages,
type 2 T helper cells (Th2), mast cells, natural killer (NK)
cells, and CD4 +CD25 + Foxp3+ regulatory T cells (Tregs).
Its primary biological function is to limit and terminate in-
flammatory responses and regulate the differentiation and
proliferation of several immune cells. IL-10 receptor 1
(IL-10R1) and IL-10R2 are two subunits of the IL-10
receptor that are expressed by hematopoietic and non-
hematopoietic cells. The receptor expression has also
been observed in endothelial cells [108,109], which pro-
vides the structural evidence for IL-10 to not only
counteract pro-inflammatory cytokines but also poten-
tially inhibit endothelial dysfunction directly. Many studies
have found that IL-10 is a key mediator of vascular pro-
tection in atherosclerosis, type II diabetes and hyperten-
sion [110-112]. IL-10 is shown to protect endothelial
function by initiating the degradation of several cytokine
mRNAs, inhibiting the production of monocyte/macro-
phage- and neutrophil-derived cytokines [113] and attenu-
ating induction of superoxide generation within the
vascular wall [114,115]. Clinically, in patients with coron-
ary artery disease, IL-10 serum level acts as an independ-
ent predictor of the endothelium-mediated vasodilator
response of the forearm circulation [116]. Furthermore,
IL-10 prevents the impairment of endothelial dysfunction
induced by elevated levels of C-reactive proteins [116].
IL-10 also attenuates inflammatory responses by its anti-
oxidant properties. It plays a protective role in blood ves-
sels by inhibiting NADPH oxidase activity and ROS
production [111,117]. In addition, IL-10 can restore Ang
II-induced endothelium-dependent relaxation impairment
measured by wire myographs in healthy murine aorta
rings [118]. Mechanistically, Ang II leads to endothelial
dysfunction by increasing gp91phox (NOX2) expression,
which is a subunit of NADPH oxidase, while IL-10 in-
hibits this response by normalizing NADPH oxidase
protein expression. In IL-10 knockout (IL-10−/−) mice,
carotid arteries and thoracic aortas show a marked aug-
mentation of vascular dysfunction after systemic treat-
ment with Ang II that can be prevented by the treatment
with superoxide dismutase-mimetic compound TEMPOL
[112]. In Ang II-infused hypertensive mice, IL-10 that is
released by transferred CD4+CD25+ natural Treg cells
from wild type mice significantly reduces NAPDH oxidase
activity and systolic blood pressure; while the transfer of
Tregs isolated from IL-10−/− mice has no effect on the
hypertension mice. Collectively, these results suggest that
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tects against Ang II-induced vascular dysfunction and
hypertension development by suppressing oxidative stress
[119].
In recent studies on aging, old IL-10−/− mice are shown
to have stiffer vessels and more severe endothelium-
dependent relaxation impairment than wild type mice,
which can be reversed by a scavenger of superoxide [120].
In addition, gp91phox is significantly induced in IL-10−/−
than that of wild type mice in aging vessels. Furthermore,
it is demonstrated that IL-10 protects against age-related
endothelial dysfunction by the inhibition of oxidative
stress. Aside from oxidative stress, it was also found that
there is an increase of COX-2 activity and consequently ac-
tivation in thromboxane A2 receptor instead of PGI2 in
older IL-10−/− mice [121].
In vitro, IL-10 suppresses the production of pro-
inflammatory cytokines such as interferon-γ (IFN-γ), IL-
1β, TNF-α, and IL-6 by immune cells including T cells,
monocytes, macrophages and dendritic cells to produce
[113,122-124]. Meanwhile, IL-10 blocks the activity of
NF-κB [125], which is a key pro-inflammatory tran-
scription factor [126-128]. In vivo, IL-10 dampens the
pro-inflammatory effects of IL-1 and TNF by stimulat-
ing IL-1Ra and soluble TNF receptors (sTNFR) produc-
tion [129]. In TNF-α-treated mouse models, impairment
of vascular relaxation is accompanied with a reduction of
eNOS, which can be counteracted by IL-10 which induces
eNOS expression and attenuates superoxide production
[130]. In addition, by using mouse aortic rings in a
myograph, TNF-α triggers a significant decrease in ACh-
induced relaxation, which can be restored by IL-10.
The Janus kinase/signal transducers and activators of
transcription (JAK/STAT) signaling pathway plays an es-
sential role in mediating the anti-inflammatory actions
of IL-10 [131]. In human EC, IL-10 up-regulates eNOS
expression and activity mediated by the activation of
STAT3 [132]. IL-10 and IL-10 receptor interaction in-
volves the JAK family tyrosine kinases Jak1 and Tyk3
that induce tyrosine phosphorylation and the activation
of latent transcription factors STAT3, STAT1, and
STAT5 [133,134]. IL-10 inhibits pro-inflammatory cyto-
kine production in the macrophages via a JAK/STAT3-
dependent pathway [135]. In IL-10−/− mice, STAT3
phosphorylation induction does not occur.
Aside from the JAK/STAT pathway, recent studies sug-
gest that IL-10 also confers endothelial protection through
several other signaling pathways. IL-10 inhibits the IL-1-
induced inhibitor of kappa B (IκB) expression, decreases
IκB phosphorylation and causes an increase in the eNOS
activity [136]. In addition, IL-10 is associated with the in-
hibition of extracellular signal-regulated protein kinases 1
and 2 (ERK1/2) activity and the MAPK kinase (MEK)/
ERK pathway [137-139]. In TNF-α-infused IL-10−/− micethere is an increase of total and phosphorylated ERK1/2
[140], and the aorta and mesenteric arteries isolated from
those mice display increased contractile responses to ET-1
through the ETA receptor, which can be abrogated by the
ERK1/2 inhibitor PD-98059. This result demonstrates that
IL-10 attenuates ET-1 induced vascular injury through the
inhibition of the ERK1/2 pathway.
Emerging evidence also suggests that IL-10 plays a
major role in suppressing endothelial dysfunction in
lipopolysaccharide (LPS)-induced endotoxemia. In LPS-
induced endotoxemia, activated ERK1/2 can induce higher
expression of IL-10. IL-10 in turn restores eNOS-mediated
relaxation by inhibiting production of ROS in monocytes
and neutrophils. Meanwhile, it also decreases the pro-
duction of pro-inflammatory cytokines such as TNF-α
and IL-6, leading to an attenuation of septic shock
[141]. Mechanistically, IL-10 inhibits the transcription
of several inflammatory genes that are induced by the
Toll-like receptor (TLR) signaling, such as COX-2, IL-8,
and IL-1 [142,143]. This response can be completely or par-
tially abrogated by the PI3K or Akt1/2 inhibitor. The PI3K-
Akt-glycogen synthase kinase 3 (GSK3) pathway regulates
IL-10-induced gene expression and controls the ability of
IL-10 to suppress a set of inflammatory genes [144].
In summary, as a cytokine synthesis inhibitor factor
(CSIF), IL-10 inhibits a broad spectrum of the functions
of activated monocytes/macrophages and T cells, includ-
ing pro-inflammatory cytokine synthesis, and NO pro-
duction. It also contributes to an essential part in the
balance between pro- and anti-inflammatory cytokines.
Transforming growth factor-β
TGF-β is a multifunctional growth factor capable of in-
ducing cell proliferation, differentiation, programmed
cell death, and stimulating matrix deposition. TGF-β
family members are also a set of pleiotropic secreted
signaling molecules with unique and potent immuno-
regulatory properties that not only significantly contrib-
ute to establishing and maintaining the vascular wall
integrity [145], but also participate in the process of
wound healing and tissue fibrosis [146,147]. Various types
of cells, such as all the immune cell lines, secrete TGF-β.
There are at least three isoforms including TGF-β1, TGF-
β2 and TGF-β3, in which TGF-β1 is predominantly ex-
pressed in the immune system and has long been known to
mediate remarkable actions in the pathogenesis of many
vascular diseases. TGF-β performs anti-inflammatory ef-
fects and plays an important role in inhibiting vascular dis-
ease. Three types of TGF-β receptors are highly expressed
in endothelial cells, in which Type I and II receptors are
expressed by all the endothelial cells while Type III recep-
tors are mainly located in microvascular endothelial cells
[148]. The expressions of TGF-β receptors in endothelial
cells provide the structural evidence for TGF-β to not only
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inhibit endothelial dysfunction directly. Moreover, a signifi-
cant increase in eNOS mRNA levels can be found in TGF-
β treated EC [149]. In D-glucose stimulated human
umbilical vein endothelium cells (HUVEC), TGF-β binds
to type II TGF-β receptors and increases L-arginine
transport and NO synthesis, which protects against
hyperglycemia-induced endothelial dysfunction [150]. In
addition, TGF-β1 knockout mice develop multifocal in-
flammatory disease associated with increased inflammatory
cytokine production, which demonstrates that TGF-β is es-
sential in immune suppression under physiological condi-
tions [151].
In EC, TGF-β increases eNOS expression by activating
Smad2, a transcription factor, which interacts with the
eNOS promoter [149]. Meanwhile, NO inversely con-
trols the transcription of TGF-β via the endothelial NO/
cGMP/PKG pathway and interferes with TGF-β/Smad2
signaling in vitro and in vivo [149,152]. With NO donor
treatment, EC show a decreased response to TGF-β and
suppressed TGF-β target gene expression. Reversely, in
eNOS deficient mice, the impairment of NO signaling
leads to the upregulation and activation of TGF-β, which
accelerates vascular injuries. These results show that the
TGF-β dependent effects are complex and can be
modulated by NO bioavailability. In response to shear
stress, TGF-β3 plays a protective role in maintaining
EC homeostasis accompanied by eNOS phosphoryl-
ation that leads to the release of NO [153]. In a high
salt intake mouse model, TGF-β induced by an excess
salt diet restores endothelial NO production via AKT
activation and NOS3 phosphorylation as well as allevi-
ates arterial compliance impairment, which forms an
inhibitory feedback loop during the vascular function
alteration [154].
The inhibitory effects of TGF-β are also in association
with Tregs, which perform important immunosuppres-
sive effects [155]. TGF-β converts CD4+CD25− effector
T cells into CD4+CD25+ Treg cells by inducing Foxp3
expression. TGF-β signaling is not only required for the
survival of peripheral Tregs, but also for the maintenance
of Treg suppressive function. Further studies found that
TGF-β1 secreted by effector T cells is dispensable for the
development and maintenance of Treg cells, while local
TGF-β1 production from infiltrating Treg cells appears to
be required for Treg immunosuppressive functions [156].
It is well known that Treg cells play an active role in the
prevention of cardiovascular diseases [157]. Treg adoptive
transfer prevents Ang II–induced hypertension and allevi-
ates aldosterone-induced impairment of the vasodilatory
response of resistance mesenteric arteries to Ach [104].
The NOS inhibitor significantly decreases the protective
effects of Treg cells, indicating that Treg cells confer pro-
tection against the Ang II induced vasodilatory responsesthrough a NO-dependent pathway. In addition, Ang II–in-
duced NADPH oxidase activity can be prevented by Treg
adoptive transfer. Thus, the suppressive function in inhi-
biting both macrophages and T lymphocytes from Tregs
is associated with Tregs’ contribution to the inhibition of
Ang II–induced oxidative stress.
All together, there is a considerable interest in TGF-β
for its potential role to be used as a therapeutic target,
which prevents endothelial dysfunction through either in-
ducing NO production or counteracting oxidative stress.Other anti-inflammatory cytokines
IL-37, previously known as IL-1 family member 7, has
been identified as a new anti-inflammatory cytokine. It
is expressed in several tissues and inflammatory cells.
Mice with transgenic expressions of IL-37 are protected
from LPS-induced endotoxemia and show markedly re-
duction of liver damage and improved lung and kidney
function [158]. Meanwhile, through the interaction with
intracellular smad3, IL-37 significantly decreases the ex-
pression of various pro-inflammatory cytokines, such as
IL-6, IL-1β, IL-17 and IFN-γ both in plasma and organs
when compared with vehicle-treat control mice. It has
also been observed that IL-37 suppresses the production
of pro-inflammatory cytokines in macrophages and epi-
thelial cells, but its role in regards to EC is yet to be
explored.
IL-33, also a member of the IL-1 cytokine family, is an-
other newly identified anti-inflammatory cytokine [159].
IL-33 shows various protective effects in the cardiovascu-
lar system when ligated with ST2 (IL-33 receptor), a
member of the Toll-interleukin 1 receptor (TIR) super-
family. IL-33 markedly decreases the aortic sinus athero-
sclerotic lesion size in apolipoprotein E (ApoE)−/− mice
fed on a high fat diet, which is accompanied by the induc-
tion of IL-4, IL-5, and IL-13 and reduction of IFN-γ in the
serum [160]. In type II diabetes, IL-33 shows protective
metabolic effects by improving insulin tolerance, as well
as reducing fasting glucose and adiposity [161]. So far, the
molecular mechanisms underlying IL-33’s protective ef-
fects are not fully understood. Recently, it was found that
IL-33 is widely expressed in normal human tissues such as
branched blood vessels, lymphoid tissues, adipocytes, car-
diac fibroblasts, and even in human tumors. As a novel
nuclear marker, IL-33 has been identified as an endogen-
ous alarm in the immune system when the endothelium
gets injured during infection and stress [162].
IL-4 and IL-13 both decrease the sensitivity of vascu-
lar EC to complement-mediated killing and apoptosis
through the activation of a PI3K/Akt Pathway [163]. In
addition, IL-4 protects EC from complement injury by
upregulating claudin-5 through JAK/STAT6 and FoxO1
activation [164].
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tified as a novel anti-inflammatory/immunosuppressive
cytokine generated by Tregs [165] and B cells [166,167].
We found that unlike IL-10 and TGF- β, IL-35 is not con-
stitutively expressed in tissues and is mainly produced by
inflammatory stimuli in EC, SMC and monocytes [168].
IL-35 also triggers CD4+CD25− T effector cell transform-
ation into CD4+CD25+ independent of Foxp3 expression.
However, the potential effect of IL-35 on endothelial dys-
function remains unknown.
MicroRNA and endothelial dysfunction
MicroRNAs (miRNAs) are a recently discovered class
of posttranscriptional modulators of gene expression that
have an essential role in vascular diseases [169,170]. They
are a group of highly conserved, small, non-coding RNAs
that, after maturation and entry into the RNA interference
pathway, inhibit specific gene expression. Specific micro-
RNAs can be regulated by inflammatory stimuli and cer-
tain microRNAs can act as mediators of inflammatory
stimuli. In a human acute monocytic leukemia cell line,
LPS stimulates the expression of miR-146a, miR-132 and
miR-155. Overexpression of miR-146a inhibits not only
the expression of interleukin-1 receptor-associated kinase
and TNF receptor-associated factor 6 s [171], but also the
expression of IL-6 and IL-8 [172,173]. In turn, the induc-
tion of miR-155, which is mediated by NFκB and the acti-
vator protein-1 (Ap-1) pathway, inhibits the expression of
IL-8 [174,175], which ultimately demonstrates a negative
feedback loop involving microRNAs in an inflammatory
response. Some miRNAs were proven to be highly
expressed in EC in vitro [176]. TNF induced miR-31, miR-
17-3p and miR-126 significantly increase the expression of
E-selectin, ICAM-1 and VCAM-1 in EC [177,178]. Trans-
fections with mimics of these miRNAs decrease neutro-
phil adhesion to EC [177]. miR-181b, which is decreased
by TNF, can down-regulate the NF-kB-responsive genes
such as VCAM-1 and E-selectin in EC in vitro and in vivo
[179]. In miR-10a knockdown human aortic EC, MCP-1
(monocyte chemotactic protein 1), IL-6, IL-8, VCAM-1
and E-selectin are highly elevated, which contributes to
athero-susceptible phenotypes in vivo [180], suggesting
that miR-10a suppresses atherogenesis.
In the aspect of regulating vascular tone, a recent report
found that miR-222/221 controls eNOS protein levels
after a member of the RNase III family know as dicer is
knockdown [181]. Induced by shear stress, miR-21 can
stimulate the phosphorylation of NOS and thereby in-
crease NO production [182]. In contrast, miR-155 causes
a reduction of NO by decreasing NOS expression [183].
In addition to mediating NO-derived vasodilation, micro-
RNAs also play a role in regulating vasoconstriction. A
recent report [184] found that miR-125a/b-5p can sup-
press oxidized low density lipoprotein (oxLDL) inducedET-1 expression by directly repressing prepro-ET-1 mRNA
expression.
In summary, working together with the classical anti-
inflammatory cytokines, anti-inflammatory/anti-athero-
genic microRNAs [169,170], as a new concept we
discussed, could be an important therapeutic target for
protecting against endothelial dysfunction and control-
ling cardiovascular diseases.
Conclusions
Endothelial dysfunction has been known as a well-
established response to cardiovascular risk factors and
precedes the development of cardiovascular diseases.
Anti-inflammatory cytokines protect against the im-
pairment of endothelial function by counteracting the
effects of pro-inflammatory cytokines and suppressing
oxidative stress. Further studies performed on the in-
hibitory properties of anti-inflammatory cytokines on
endothelial dysfunction may provide novel promising
therapeutic strategies for the treatment of cardiovas-
cular diseases.
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